NERVGEN PHARMA CORP.
No SEC Form 4 filings for $NGEN in the last 30 days.
See all $NGEN insider activity →NervGen (NGEN) will restate its 2025 annual and Q2 2026 financial statements, reducing stock-based compensation expense and warrant liabilities. The non-cash adjustments do not affect cash, cash equivalents, or operations. The company expects to file restated statements soon and remains on track to report Q3 2026 results.
NervGen (NASDAQ: NGEN) reported Q2 2026 results and updates for its Phase 3 RESTORE study of NVG-291 in chronic cervical spinal cord injury. It said FDA alignment is in place, site activation and screening start in Sept 2026, enrollment completion is expected in 2H 2027, and topline data are expected in 1H 2028. Cash was C$86.8M (US$61.1M) at June 30, 2026; R&D rose to C$7.9M and net loss was C$29.2M.
NervGen Pharma said independent, blinded biomechanical gait analyses in its Phase 1b/2a CONNECT SCI study found NVG-291 produced “genuine neural recovery” signals versus placebo. The Global Statistical Test showed a significant global treatment effect (GTE +0.45; p=0.0197) and 100% (10/10) responders vs 10% (1/10) placebo (p=0.0001), with consistent improvements across coordination, mechanical effort and postural stability.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NGEN (NERVGEN PHARMA CORP.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent NGEN coverage spans corporate actions, earnings and technology.
Restatement is non‑cash and does not affect cash runway, but reduces reported expenses and liabilities, which may modestly improve balance‑sheet perception.
The update is a funding and execution catalyst for NGEN, extending runway and setting concrete next trial milestones (site activation, screening, enrollment completion, topline timing).
Positive independent gait biomarker results strengthen efficacy credibility for NVG-291 and support the Phase 3 RESTORE registrational path.
AlphAI scores every news story that mentions NGEN with an AI model for sentiment and relevance, and aggregates insider trades from NERVGEN PHARMA CORP.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NervGen (NGEN) will restate its 2025 annual and Q2 2026 financial statements, reducing stock-based compensation expense and warrant liabilities. The non-cash adjustments do not affect cash, cash equivalents, or operations. The company expects to file restated statements soon and remains on track to report Q3 2026 results.
2 min readNervGen (NASDAQ: NGEN) reported Q2 2026 results and updates for its Phase 3 RESTORE study of NVG-291 in chronic cervical spinal cord injury. It said FDA alignment is in place, site activation and screening start in Sept 2026, enrollment completion is expected in 2H 2027, and topline data are expected in 1H 2028. Cash was C$86.8M (US$61.1M) at June 30, 2026; R&D rose to C$7.9M and net loss was C$29.2M.
7 min readNervGen Pharma said independent, blinded biomechanical gait analyses in its Phase 1b/2a CONNECT SCI study found NVG-291 produced “genuine neural recovery” signals versus placebo. The Global Statistical Test showed a significant global treatment effect (GTE +0.45; p=0.0197) and 100% (10/10) responders vs 10% (1/10) placebo (p=0.0001), with consistent improvements across coordination, mechanical effort and postural stability.
5 min read
